Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
相关临床试验
56
24 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1979
进行中（未招募）
24
42.9%
已完成
27
48.2%
招募中
1
1.8%
终止
3
5.4%
撤回
1
1.8%
暂无批准数据
- Inovio Pharmaceuticals is awaiting an Oct. 30 FDA target action date for INO-3107, an investigational DNA medicine for HPV 6- and HPV 11-associated recurrent respiratory papillomatosis. - In the Phase I/II RRP-001 study, 72% of patients had a 50% to 100% surgery reduction in year one, rising to 86% in year two. - The BLA was filed under accelerated approval, but the FDA's file acceptance letter preliminarily questioned eligibility because an RRP product already holds full approval. - Inovio has completed pre-licensure inspections and expects labeling discussions in September, while a confirmatory trial design still requires FDA agreement.
- Luye Pharma is advancing its LY01620 mRNA therapeutic vaccine into Phase II development in China for HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL). - Phase I data reported an HPV clearance rate of approximately 90%, with histopathological improvement that "nearly reached" surgical treatment outcomes. - LY01620 encodes the HPV16 E6 and E7 oncoproteins to induce antigen-specific immune responses against HPV-infected cells, offering a potential non-surgical alternative that preserves reproductive function. - The candidate may also extend into HPV-associated solid tumors, strengthening Luye's position in mRNA oncology and women's health.
- The global vaccine sales market is projected to reach US$141.40 billion by 2036, driven by next-generation platforms including mRNA and viral vector technologies. - U.S. tariff policies and cross-border supply chain vulnerabilities are reshaping competitive strategy, with manufacturers localizing production and diversifying suppliers to manage cost pressures. - Competition is increasingly defined by platform capabilities, regulatory credentials, manufacturing scale, and access to government and multilateral procurement contracts. - The report profiles 21 leading vaccine companies including GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca, and Serum Institute of India, with forecasts across 26 national markets.
- INOVIO and Akeso have entered a clinical collaboration to evaluate INO-5412 combined with cadonilimab for treating glioblastoma, the most aggressive form of brain cancer. - The combination therapy will be studied in the Phase 2 INSIGhT adaptive platform trial sponsored by Dana-Farber Cancer Institute, with dosing expected to begin in the second half of 2026. - The study builds on positive Phase 2 results for INO-5401 in GBM patients, adding cadonilimab's dual PD-1/CTLA-4 checkpoint inhibition to potentially enhance treatment efficacy. - Cadonilimab is the world's first approved PD-1/CTLA-4 bispecific antibody, already approved in China for multiple cancer indications and demonstrating effectiveness regardless of PD-L1 expression status.
- Inovio Pharmaceuticals has completed its rolling Biologics License Application (BLA) submission to the FDA for INO-3107, a DNA immunotherapy targeting recurrent respiratory papillomatosis (RRP). - Clinical data showed 86% of patients experienced reduced surgical procedures in the second year of treatment, with half requiring no surgeries at all. - The FDA could deliver a final approval decision by mid-2026 if priority review is granted, potentially making INO-3107 the first DNA medicine approved in the United States. - The company raised $25 million in November 2025 to fund potential commercial launch preparations and confirmatory trial requirements.
- INOVIO's Phase 1 trial demonstrated that DNA-encoded monoclonal antibodies (DMAbs) achieved sustained expression in all 39 participants through 72 weeks of follow-up, with peak serum concentrations reaching 1.61 μg/mL. - The synthetic DNA technology enabled in vivo production of monoclonal antibodies directly from muscle cells using intramuscular injection and electroporation delivery, avoiding viral vectors and lipid nanoparticles. - No anti-drug antibodies were detected in approximately 1,000 blood samples, addressing a key limitation of other gene-based delivery platforms while maintaining excellent safety profile. - Results published in Nature Medicine confirm the expressed antibodies successfully bound SARS-CoV-2 spike protein and neutralized pseudovirus in all tested participants.
- INOVIO's DNA medicine INO-3107 demonstrated improved long-term efficacy in treating Recurrent Respiratory Papillomatosis, with overall response rates increasing from 72% in Year 1 to 86% in Year 2. - Complete response rates nearly doubled from 28% to 50% between Year 1 and Year 2, while mean annual surgeries dropped 78% from 4.1 pre-treatment to 0.9 in Year 2. - The retrospective study published in The Laryngoscope followed 28 patients for a median of 2.8 years, showing sustained clinical benefits without serious adverse events. - INO-3107 has received FDA Orphan Drug and Breakthrough Therapy designations and is eligible for accelerated approval pathway submission.
- Piper Sandler initiated coverage of Inovio Pharmaceuticals with an Overweight rating, driving shares up approximately 4% in morning trading on Tuesday. - The bullish recommendation centers on the potential FDA approval of Inovio's lead asset INO-3107, which analyst Edward Tenthoff expects could occur next year. - The DNA medicines developer's stock gained momentum following the analyst's positive outlook on the regulatory prospects for its flagship therapeutic candidate.
- Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline. - Liebowitz brings over 30 years of experience in oncology drug development and has contributed to more than 25 Investigational New Drug applications throughout his career. - The company also appointed Yulii Bogatyrenko as business development advisor to strengthen corporate growth strategy and pipeline advancement. - These appointments come at a pivotal time as Avacta continues to advance its pre|CISION platform for targeted oncology drug delivery.
- INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events. - Ocugen and Washington University prepare to launch a Phase I trial for OCU500 nasal vaccine in Q2 2025, testing both intranasal and inhalation delivery methods across multiple dosing groups. - Pfizer initiates a Phase III trial for ibuzatrelvir, an oral antiviral candidate targeting non-hospitalized COVID-19 patients at high risk of disease progression, aiming to enroll 2,330 participants.
